‘ChatGPT for Doctors’ OpenEvidence Raises $250M, Quietly Pivots Into Drug Development

{
  "signal_id": "3574a6cd-81bd-6e00-fb46-e3f664d0130a",
  "signal_type": "news",
  "signal_subtype": "receives_financing",
  "detected_at": "2026-09-27T23:30:18+00:00",
  "company": {
    "name": "Abridge",
    "domain": "abridge.com"
  },
  "data": {
    "url": "https://en.wowtale.net/2026/09/28/235252/",
    "title": "‘ChatGPT for Doctors’ OpenEvidence Raises $250M, Quietly Pivots Into Drug Development - Wowtale",
    "excerpt": "The market for AI-powered clinical search is heating up. Publicly traded Doximity told investors its AI Scribe user base nearly tripled in a single quarter, while Abridge took a strategic equity investment from Eli Lilly and is expanding into clinical-trial patient recruitment. Even OpenEvidence , the company that built the “ChatGPT for doctors” category, isn’t immune to that pressure. OpenEvidence raised another $250 million, Forbes reported . The company itself never put out a press release. What stands out is how quietly it landed: unlike January’s Series D - a $12 billion valuation announced with a CNBC appearance for the CEO - this one surfaced as a single sentence buried inside a Forbes story about a hospital partnership. CEO Daniel Nadler told Forbes that OpenEvidence is moving into developing its own cancer drugs, with a first candidate entering clinical trials before year-end and three to five more next year, starting with rare cancers. Rather than go head-to-head with Eli Lilly or Pfizer on large trials, Nadler said the company is targeting “the stuff that they are not doing, and maybe can’t do” - the bet being that reaching most of America’s physicians makes it far easier to find the handful of patients a rare-disease trial needs. The partnership announced the same day is the first building block. MSK and OpenEvidence said they’re integrating OpenEvidence into MSK’s...",
    "summary": "Abridge received a strategic equity investment from Eli Lilly to expand into clinical-trial patient recruitment.",
    "planning": false,
    "image_url": "https://cdn.wowtale.net/wp-content/uploads/sites/2/2026/09/open-evidence-logo-1024x538.jpg",
    "confidence": 0.9,
    "published_at": "2026-09-27T23:30:18Z",
    "article_sentence": "Abridge took a strategic equity investment from Eli Lilly and is expanding into clinical-trial patient recruitment.",
    "financing_type_tags": [
      "equity"
    ],
    "related_company_name": "Eli Lilly and Company",
    "related_company_domain": "lilly.com"
  }
}

curl https://signals.autobound.ai/v1/signals/3574a6cd-81bd-6e00-fb46-e3f664d0130a \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abridge.com","limit":20}'